Drugs / JS207
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06571422 | Oct 2024 → Dec 2026 expected | cancer | Shanghai Junshi Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06022250 | Sep 2023 → Apr 2026 overdue | cancer | Shanghai Junshi Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07466160 | Feb 2026 → Dec 2027 expected | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06953323 | Jul 2025 → Jun 2029 expected | neoplasm | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07690787 | Jun 2026 → Dec 2027 expected | nasopharyngeal carcinoma | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT07503756 | Apr 2026 → Dec 2027 expected | colorectal cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07480733 | Apr 2026 → Nov 2027 expected | cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07309276 | Jan 2026 → Nov 2027 expected | lung cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07045311 | Sep 2025 → Mar 2028 expected | triple-negative breast carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06924606 | Jul 2025 → Jun 2026 overdue | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06969027 | Jun → Nov 2025 overdue | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06954467 | May 2025 → Dec 2027 expected | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06885385 | Apr 2025 → Nov 2026 expected | colorectal cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06944470 | Apr 2025 → Sep 2026 expected | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06868836 | Mar 2025 → Sep 2026 expected | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06953323 ↗ |
| Modality | Monoclonal antibody | “an anti-PD-1/VEGF bispecific antibody” NCT05582499 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT06022250 ↗ |